



Clinical trial results:

A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176/GSK3532795, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults

Summary

EudraCT number	2013-005487-26
Trial protocol	DE ES GB IT
Global end of trial date	

Results information

Result version number	v1
This version publication date	09 August 2017
First version publication date	09 August 2017

Trial information

Trial identification

Sponsor protocol code	205891
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	ViiV Healthcare
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	16 June 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	26 May 2016
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate antiviral efficacy of 3 doses (60, 120 and 180 mg) of BMS-955176/GSK3532795, and EFV, each when given in combination with TDF/FTC in treatment-naïve subjects by determining the proportion of treatment-naïve subjects with plasma HIV-1 RNA < 40 c/mL at Week 24

Protection of trial subjects:

NA

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 May 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 41
Country: Number of subjects enrolled	Canada: 24
Country: Number of subjects enrolled	Chile: 20
Country: Number of subjects enrolled	France: 11
Country: Number of subjects enrolled	Germany: 23
Country: Number of subjects enrolled	Italy: 17
Country: Number of subjects enrolled	Mexico: 40
Country: Number of subjects enrolled	Poland: 15
Country: Number of subjects enrolled	Puerto Rico: 7
Country: Number of subjects enrolled	South Africa: 45
Country: Number of subjects enrolled	Spain: 20
Country: Number of subjects enrolled	United Kingdom: 4
Country: Number of subjects enrolled	United States: 38
Worldwide total number of subjects	305
EEA total number of subjects	90

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	302
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 305 participants were enrolled, of which 210 were randomized to 1 of 4 treatment arms. Of 210 participants only 206 received randomized treatment. The study was originally designed for 96 weeks of treatment, but it was terminated early. Study results through the primary completion achieved at Week 24 were presented.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

Arms

Are arms mutually exclusive?	Yes
Arm title	BMS-955176/GSK3532795 60 mg + TDF/FTC

Arm description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 milligrams (mg) active dose, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing efavirenz (EFV) placebo matching 600 mg from Day 1 to Week 48.

Arm type	Experimental
Investigational medicinal product name	BMS-955176/GSK3532795 60mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 60 mg active dose.

Investigational medicinal product name	Placebo to match BMS-955176/GSK3532795 120 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 placebo matching 120 mg.

Investigational medicinal product name	Placebo to match EFV 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg.

Investigational medicinal product name	TDF/FTC 300 mg/ 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing open-label TDF/FTC 300 mg/ 200 mg.

Arm title	BMS-955176/GSK3532795 120 mg + TDF/FTC
------------------	--

Arm description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 120 mg active dose, BMS-955176/GSK3532795 placebo matching 60 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg from Day 1 to Week 48.

Arm type	Experimental
Investigational medicinal product name	BMS-955176/GSK3532795 120 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 120 mg active dose.

Investigational medicinal product name	Placebo to match BMS-955176/GSK3532795 60 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 placebo matching 60 mg.

Investigational medicinal product name	Placebo to match EFV 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg.

Investigational medicinal product name	TDF/FTC 300 mg/ 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing open-label TDF/FTC 300 mg/ 200 mg.

Arm title	BMS-955176/GSK3532795 180 mg + TDF/FTC
------------------	--

Arm description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 mg active dose, BMS-955176/GSK3532795 120 mg active dose and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg from Day 1 to Week 48.

Arm type	Experimental
Investigational medicinal product name	BMS-955176/GSK3532795 60mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 60 mg active dose.

Investigational medicinal product name	BMS-955176/GSK3532795 120 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 120 mg active dose.

Investigational medicinal product name	Placebo to match EFV 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg.

Investigational medicinal product name	TDF/FTC 300 mg/ 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing open-label TDF/FTC 300 mg/ 200 mg.

Arm title	EFV 600 mg + TDF/FTC
------------------	----------------------

Arm description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 placebo matching 60 mg, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV 600 mg active dose from Day 1 to Week 48.

Arm type	Experimental
Investigational medicinal product name	Placebo to match BMS-955176/GSK3532795 60 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 placebo matching 60 mg.

Investigational medicinal product name	Placebo to match BMS-955176/GSK3532795 120 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 placebo matching 120 mg.

Investigational medicinal product name	EFV 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV 600 mg.

Investigational medicinal product name	TDF/FTC 300 mg/ 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing open-label TDF/FTC 300 mg/ 200 mg.

Number of subjects in period 1^[1]	BMS-955176/GSK353279 5 60 mg + TDF/FTC	BMS-955176/GSK353279 5 120 mg + TDF/FTC	BMS-955176/GSK353279 5 180 mg + TDF/FTC
Started	50	52	51
Completed	0	0	0
Not completed	50	52	51
Consent withdrawn by subject	3	-	1
Adverse event, non-fatal	1	3	5
Study terminated by sponsor	42	42	42
Poor/Non-compliance	-	-	1
Lost to follow-up	-	1	-
Subject no longer meets study criteria	-	1	1
Lack of efficacy	3	4	-
Participant request to discontinue study treatment	1	-	-
Concerns about the safety of treatment	-	1	-
Discontinuation due to NRTI resistance	-	-	1

Number of subjects in period 1^[1]	EFV 600 mg + TDF/FTC
Started	53
Completed	0
Not completed	53
Consent withdrawn by subject	-
Adverse event, non-fatal	9

Study terminated by sponsor	43
Poor/Non-compliance	-
Lost to follow-up	-
Subject no longer meets study criteria	-
Lack of efficacy	-
Participant request to discontinue study treatment	1
Concerns about the safety of treatment	-
Discontinuation due to NRTI resistance	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: A total of 305 participants were enrolled, of which 210 were randomized and only 206 received randomized treatment.

Baseline characteristics

Reporting groups

Reporting group title	BMS-955176/GSK3532795 60 mg + TDF/FTC
Reporting group description:	
In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 milligrams (mg) active dose, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing efavirenz (EFV) placebo matching 600 mg from Day 1 to Week 48.	
Reporting group title	BMS-955176/GSK3532795 120 mg + TDF/FTC
Reporting group description:	
In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 120 mg active dose, BMS-955176/GSK3532795 placebo matching 60 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg from Day 1 to Week 48.	
Reporting group title	BMS-955176/GSK3532795 180 mg + TDF/FTC
Reporting group description:	
In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 mg active dose, BMS-955176/GSK3532795 120 mg active dose and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg from Day 1 to Week 48.	
Reporting group title	EFV 600 mg + TDF/FTC
Reporting group description:	
In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 placebo matching 60 mg, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV 600 mg active dose from Day 1 to Week 48.	

Reporting group values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC
Number of subjects	50	52	51
Age categorical			
Units: Subjects			

Age continuous			
Treated Subjects Population, also known as the modified intent-to-treat (mITT) population, comprised of all subjects who received at least one dose of study treatment, was used to present baseline characteristics			
Units: years			
arithmetic mean	31.8	34.7	35.5
standard deviation	± 8.26	± 11.29	± 11.34
Gender categorical			
Treated Subjects Population was used to present Baseline characteristics			
Units:			
Male	42	44	44
Female	8	8	7
Race/Ethnicity, Customized			
Treated Subjects Population was used to present Baseline characteristics			
Units: Subjects			

White	39	38	41
Black or African American	8	10	6
American Indian or Alaska Native	0	0	1
Unknown	3	4	3

Reporting group values	EFV 600 mg + TDF/FTC	Total	
Number of subjects	53	206	
Age categorical			
Units: Subjects			

Age continuous			
----------------	--	--	--

Treated Subjects Population, also known as the modified intent-to-treat (mITT) population, comprised of all subjects who received at least one dose of study treatment, was used to present baseline characteristics

Units: years			
arithmetic mean	32.9		
standard deviation	± 9.35	-	

Gender categorical			
--------------------	--	--	--

Treated Subjects Population was used to present Baseline characteristics

Units:			
Male	46	176	
Female	7	30	

Race/Ethnicity, Customized			
----------------------------	--	--	--

Treated Subjects Population was used to present Baseline characteristics

Units: Subjects			
White	40	158	
Black or African American	9	33	
American Indian or Alaska Native	0	1	
Unknown	4	14	

End points

End points reporting groups

Reporting group title	BMS-955176/GSK3532795 60 mg + TDF/FTC
Reporting group description: In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 milligrams (mg) active dose, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing efavirenz (EFV) placebo matching 600 mg from Day 1 to Week 48.	
Reporting group title	BMS-955176/GSK3532795 120 mg + TDF/FTC
Reporting group description: In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 120 mg active dose, BMS-955176/GSK3532795 placebo matching 60 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg from Day 1 to Week 48.	
Reporting group title	BMS-955176/GSK3532795 180 mg + TDF/FTC
Reporting group description: In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 mg active dose, BMS-955176/GSK3532795 120 mg active dose and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg from Day 1 to Week 48.	
Reporting group title	EFV 600 mg + TDF/FTC
Reporting group description: In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 placebo matching 60 mg, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV 600 mg active dose from Day 1 to Week 48.	

Primary: Number of participants with plasma HIV-1 ribonucleic acid (RNA) < 40 copies per milliliter (c/mL) at Week 24 using food and drug administration (FDA) snapshot algorithm

End point title	Number of participants with plasma HIV-1 ribonucleic acid (RNA) < 40 copies per milliliter (c/mL) at Week 24 using food and drug administration (FDA) snapshot algorithm ^[1]
End point description: The antiviral efficacy was determined by the number of participants with plasma HIV 1 RNA < 40 c/mL at Week 24 using the FDA snapshot algorithm. This used the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window to determine response. Plasma samples were collected for HIV-1 RNA at Week 0 (Day 1), Week 2 (Day 12 to 16), Week 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84 and 96. The analysis was based on a modified Intent-to-Treat (mITT) approach. The Treated Subjects Population includes randomized participants who received at least 1 dose of BMS-955176/GSK3532795 or EFV.	
End point type	Primary
End point timeframe: Week 24	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.	

End point values	BMS- 955176/GSK35 32795 60 mg + TDF/FTC	BMS- 955176/GSK35 32795 120 mg + TDF/FTC	BMS- 955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[2]	52 ^[3]	51 ^[4]	53 ^[5]
Units: Participants	38	43	42	41

Notes:

[2] - Treated Subjects Population

[3] - Treated Subjects Population

[4] - Treated Subjects Population

[5] - Treated Subjects Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with plasma HIV-1 RNA < 40 c/mL at Week 48 and 96 using FDA snapshot algorithm

End point title	Number of participants with plasma HIV-1 RNA < 40 c/mL at Week 48 and 96 using FDA snapshot algorithm
-----------------	---

End point description:

The antiviral efficacy was planned to be determined by the number of participants with plasma HIV 1 RNA < 40 c/mL at Week 48 and 96 using the FDA snapshot algorithm. This would use the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window to determine response. Plasma samples were to be collected for HIV-1 RNA at Week 0 (Day 1), Week 2 (Day 12 to 16), Week 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84 and 96. The analysis was based on a modified Intent-to-Treat (mITT) . As the study was terminated early, this outcome was not analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 48 and 96

End point values	BMS- 955176/GSK35 32795 60 mg + TDF/FTC	BMS- 955176/GSK35 32795 120 mg + TDF/FTC	BMS- 955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[6]	0 ^[7]	0 ^[8]	0 ^[9]
Units: Participants				

Notes:

[6] - The study was terminated early, this outcome was not analyzed.

[7] - The study was terminated early, this outcome was not analyzed.

[8] - The study was terminated early, this outcome was not analyzed.

[9] - The study was terminated early, this outcome was not analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with plasma HIV-1 RNA < 200 c/mL at Week 24 using FDA snapshot algorithm

End point title	Number of participants with plasma HIV-1 RNA < 200 c/mL at Week 24 using FDA snapshot algorithm
-----------------	---

End point description:

The antiviral efficacy was to be determined by the number of participants with plasma HIV 1 RNA < 40 c/mL at Week 24, 48 and 96 using the FDA snapshot algorithm. This use the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window to determine response. Plasma samples were to be collected for HIV-1 RNA at Week 0 (Day 1), Week 2 (Day 12 to 16), Week 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84 and 96. Positive response was defined as HIV-1 RNA < 200 c/mL. The analysis was based on a modified Intent-to-Treat (mITT) approach. The Treated Subjects Population includes randomized participants who received at least 1 dose of BMS-955176/GSK3532795 or EFV

End point type	Secondary
----------------	-----------

End point timeframe:

Week 24

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[10]	52 ^[11]	51 ^[12]	53 ^[13]
Units: Participants	40	44	43	44

Notes:

[10] - Treated Subjects Population

[11] - Treated Subjects Population

[12] - Treated Subjects Population

[13] - Treated Subjects Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with newly emergent genotypic resistance using all on-treatment isolates

End point title	Number of participants with newly emergent genotypic resistance using all on-treatment isolates
-----------------	---

End point description:

The emergence of HIV drug resistance among samples selected for drug resistance testing were assessed using the most recent version of the international acquired immunodeficiency syndrome (AIDS) society United States of America (IAS-USA) list of HIV-1 drug resistance mutations. Samples for emergent drug resistance testing (genotypic) were collected at Week 4, 8, 12, 16 and 24. Treated participants with on-treatment genotypic resistance sequenced were summarized. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 24 as the study was terminated early. Outcome results through Week 24 were presented. Treated Subjects Population who had Baseline and on-treatment genotypic resistance testing and who had successful sequencing

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 24 weeks

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5 ^[14]	5 ^[15]	2 ^[16]	1 ^[17]
Units: Participants				
Protease inhibitor substitution	1	0	0	0
Reverse transcriptase substitution	3	5	2	0

Notes:

[14] - Treated Subjects Population

[15] - Treated Subjects Population

[16] - Treated Subjects Population

[17] - Treated Subjects Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with newly emergent phenotypic resistance using all on-treatment isolates

End point title	Number of participants with newly emergent phenotypic resistance using all on-treatment isolates
-----------------	--

End point description:

The emergence of HIV drug resistance among samples selected for drug resistance testing were assessed using the most recent version of the international AIDS IAS-USA list of HIV-1 drug resistance mutations. Samples for emergent drug resistance testing (phenotypic) were collected at Week 4, 8, 12, 16 and 24. Emergent phenotypic resistance to BMS-955176/GSK3532795 was defined as a Baseline fold change half maximal inhibitory concentration (IC₅₀) ≤ 3 and an on-treatment fold change IC₅₀ > 3. Treated participants with on-treatment phenotypic resistance tested were summarized. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 24 as the study was terminated early. Outcome results through Week 24 were presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 24 weeks

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[18]	3 ^[19]	0 ^[20]	1 ^[21]
Units: Participants	1	0		0

Notes:

[18] - Treated Subjects Population who had Baseline and on-treatment phenotypic resistance testing.

[19] - Treated Subjects Population who had Baseline and on-treatment phenotypic resistance testing.

[20] - Treated Subjects Population who had Baseline and on-treatment phenotypic resistance testing.

[21] - Treated Subjects Population who had Baseline and on-treatment phenotypic resistance testing.

Statistical analyses

No statistical analyses for this end point

Secondary: Changes from Baseline in log10 HIV-1 RNA over time

End point title	Changes from Baseline in log10 HIV-1 RNA over time
-----------------	--

End point description:

Plasma samples were collected for HIV-1 RNA at Week 0 (Day 1), Week 2 (Day 12 to 16), Week 4, 8, 12, 16, 24, 32, 40 and 48. Values obtained at Day 1 were considered as Baseline value. Change from Baseline over time in log 10 HIV-1 RNA overall was presented from on-treatment laboratory results and pre-specified visit windows. Change from Baseline was calculated as value at indicated time point minus Baseline value. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 48 as the study was terminated early. Outcome results through Week 48 were presented. Only those participants with data available at the specified time points were analyzed (represented by n=X, X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and at Week 2 (Day 12 to 16), 4, 8, 12, 16, 24, 32, 40 and 48

End point values	BMS-955176/GSK35 32795 60 mg + TDF/FTC	BMS-955176/GSK35 32795 120 mg + TDF/FTC	BMS-955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[22]	52 ^[23]	51 ^[24]	53 ^[25]
Units: log 10 c/mL				
arithmetic mean (standard deviation)				
Week 4, n=50, 51, 51, 48	-2.082 (± 0.587)	-2.074 (± 0.5382)	-2.143 (± 0.5093)	-2.315 (± 0.4597)
Week 8, n=49, 51, 49, 48	-2.308 (± 0.6995)	-2.254 (± 0.7096)	-2.335 (± 0.6041)	-2.515 (± 0.6402)
Week 12, n=49, 50, 47, 47	-2.372 (± 0.8221)	-2.343 (± 0.7584)	-2.442 (± 0.6373)	-2.73 (± 0.6252)
Week 16, n=47, 50, 46, 45	-2.503 (± 0.8656)	-2.423 (± 0.7964)	-2.514 (± 0.6426)	-2.876 (± 0.6909)
Week 24, n=46, 47, 45, 44	-2.506 (± 0.8103)	-2.548 (± 0.7937)	-2.507 (± 0.7279)	-2.919 (± 0.7586)
Week 32, n=41, 38, 34, 37	-2.517 (± 0.8039)	-2.66 (± 0.7349)	-2.582 (± 0.6551)	-2.878 (± 0.7542)
Week 40, n=8, 7, 9, 10	-2.913 (± 0.5622)	-2.846 (± 0.5992)	-2.673 (± 0.5465)	-2.829 (± 0.7215)
Week 48, n=5, 4, 3, 6	-2.408 (± 0.6076)	-2.538 (± 0.5144)	-2.767 (± 0.678)	-2.97 (± 0.5908)

Notes:

[22] - Treated Subjects Population

[23] - Treated Subjects Population

[24] - Treated Subjects Population

[25] - Treated Subjects Population

Statistical analyses

No statistical analyses for this end point

Secondary: Changes from Baseline in cluster designation (CD)4+ thymus (T)-cell counts over time

End point title	Changes from Baseline in cluster designation (CD)4+ thymus (T)-cell counts over time
-----------------	--

End point description:

Plasma samples were collected for CD4+ T-cell counts at Week 0 (Day 1) and at Week 4, 8, 12, 16, 24,

32, 40 and 48. Values obtained at Day 1 were considered as Baseline value. Change from Baseline over time in CD4+ T-cell counts overall was assessed using flow cytometry. Change from Baseline was calculated as value at indicated time point minus Baseline value. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 48 as the study was terminated early. Outcome results through Week 48 were presented. Only those participants with data available at the specified time points were analyzed (represented by n=X, X in the category titles).

End point type	Secondary
End point timeframe:	
Baseline (Day 1) and at Week 4, 8, 12, 16, 24, 32, 40 and 48	

End point values	BMS-955176/GSK35 32795 60 mg + TDF/FTC	BMS-955176/GSK35 32795 120 mg + TDF/FTC	BMS-955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[26]	52 ^[27]	51 ^[28]	53 ^[29]
Units: Cells per uL				
arithmetic mean (standard deviation)				
Week 4, n=50, 51, 50, 48	41.6 (± 148.92)	71.5 (± 169.22)	52.9 (± 149.54)	71.1 (± 145.01)
Week 8, n=48, 49, 49, 47	59.1 (± 219.64)	80.4 (± 127.52)	88.4 (± 177.68)	117.4 (± 230.74)
Week 12, n=49, 49, 47, 47	110.4 (± 170.87)	118.6 (± 179.42)	129.7 (± 175.73)	142.5 (± 118.39)
Week 16, n=46, 50, 46, 46	90.8 (± 200.76)	98.4 (± 173.53)	128 (± 212.09)	140.5 (± 179.7)
Week 24, n=46, 46, 44, 44	94.3 (± 175)	79.7 (± 199.46)	92.5 (± 144.04)	134.7 (± 151.7)
Week 32, n=42, 39, 38, 41	114.8 (± 190.12)	96.2 (± 167.77)	97.7 (± 174.75)	171.5 (± 148.97)
Week 40, n=9, 7, 9, 11	176.1 (± 161.74)	342.3 (± 250.51)	152.8 (± 219.04)	199.3 (± 161.07)
Week 48, n=5, 4, 3, 6	94.6 (± 105.21)	194.5 (± 130.27)	28.7 (± 90.61)	289 (± 244.9)

Notes:

[26] - Treated Subjects Population

[27] - Treated Subjects Population

[28] - Treated Subjects Population

[29] - Treated Subjects Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the percentage of CD4+ T-cells over time

End point title	Change from Baseline in the percentage of CD4+ T-cells over time
-----------------	--

End point description:

Plasma samples were collected for CD4+ T-cell counts at Week 0 (Day 1) and at Week 4, 8, 12, 16, 24, 32, 40 and 48. Values obtained at Day 1 were considered as Baseline value. Change in the percentage of CD4+ T-cell counts overall was assessed using flow cytometry. Change from Baseline was calculated as value at indicated time point minus Baseline value. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 48 as the study was terminated early. Outcome results through Week 48 were presented. Only those participants with data available at the specified time points were analyzed (represented by n=X, X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and at Week 4, 8, 12, 16, 24, 32, 40 and 48

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[30]	52 ^[31]	51 ^[32]	53 ^[33]
Units: Percentage				
arithmetic mean (standard deviation)				
Week 4, n=50, 51, 50, 48	4.56 (± 3.195)	3.54 (± 4.077)	3.93 (± 3.21)	3.84 (± 4.339)
Week 8, n=48, 49, 49, 47	5.02 (± 4.65)	4.27 (± 4.116)	5.15 (± 3.943)	5.09 (± 4.257)
Week 12, n=49, 49, 47, 47	5.47 (± 4.57)	5.51 (± 4.643)	6.22 (± 4.45)	6.29 (± 4.557)
Week 16, n=46, 50, 46, 46	6.2 (± 6.163)	5.77 (± 4.117)	6.95 (± 4.019)	6.87 (± 4.763)
Week 24, n=46, 46, 44, 44	7.68 (± 5.834)	5.84 (± 4.457)	6.96 (± 4.761)	5.94 (± 5.73)
Week 32, n=42, 39, 38, 41	7.46 (± 6.578)	7.63 (± 5.334)	7.07 (± 6.756)	8.31 (± 6.447)
Week 40, n=9, 7, 9, 11	9.56 (± 8.395)	11.01 (± 7.421)	10.32 (± 6.567)	10.5 (± 5.415)
Week 48, n=5, 4, 3, 6	6.82 (± 6.9)	7.8 (± 3.057)	13.9 (± 7.545)	11.77 (± 4.238)

Notes:

[30] - Treated Subjects Population

[31] - Treated Subjects Population

[32] - Treated Subjects Population

[33] - Treated Subjects Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with at least one adverse event (AE) and with AE leading to discontinuation (AELD)

End point title	Number of participants with at least one adverse event (AE) and with AE leading to discontinuation (AELD)
-----------------	---

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention were categorized as SAE. Number of participants with at least one AE or SAE or with AELD up to Week 24 was summarized. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 24 as the study was terminated early. Outcome results through Week 24 were presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 24 weeks

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[34]	52 ^[35]	51 ^[36]	53 ^[37]
Units: Participants				
At least one AE	41	45	45	48
AELD	1	3	4	9

Notes:

[34] - Treated Subjects Population

[35] - Treated Subjects Population

[36] - Treated Subjects Population

[37] - Treated Subjects Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with at least one centers for disease control (CDC) class C AIDS event

End point title	Number of participants with at least one centers for disease control (CDC) class C AIDS event
End point description: Number of participants with at least one CDC class C AIDS event was summarized. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 24 as the study was terminated early. Outcome results through Week 24 were presented.	
End point type	Secondary
End point timeframe: Up to 24 weeks	

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[38]	52 ^[39]	51 ^[40]	53 ^[41]
Units: Participants	0	1	0	0

Notes:

[38] - Treated Subjects Population

[39] - Treated Subjects Population

[40] - Treated Subjects Population

[41] - Treated Subjects Population

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum observed plasma concentration (C_{max}), observed pre-dose plasma concentration (C₀) and observed plasma concentration at the end of a dosing interval (C_{tau}) of BMS-955176/GSK3532795

End point title	Maximum observed plasma concentration (C _{max}), observed pre-dose plasma concentration (C ₀) and observed plasma
-----------------	---

End point description:

Cmax, C0 and Ctau was evaluated from the blood samples collected at pre-dose (morning) and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 and 24 hours after administration of BMS-955176/GSK3532795 60 mg or 120 mg or 180 mg with TDF/ FTC on study Week 2 (Days 12 to 16). The evaluable pharmacokinetic (PK) Population was a sub-population including all treated participants who had adequate PK profiles.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (morning) and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 and 24 hours on study Week 2 (Days 12 to 16)

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8 ^[43]	6 ^[44]	10 ^[45]	
Units: Nanogram per milliliter				
geometric mean (geometric coefficient of variation)				
Cmax	1945.342 (± 16)	3162.161 (± 28.8)	4645.266 (± 16.2)	
C0	1065.102 (± 25.2)	1800.952 (± 33.4)	2728.671 (± 17.8)	
Ctau	1100.138 (± 15.1)	1656.578 (± 39.7)	2705.751 (± 26.8)	

Notes:

[43] - Evaluable PK Population

[44] - Evaluable PK Population

[45] - Evaluable PK Population

Statistical analyses

No statistical analyses for this end point

Secondary: Time of maximum observed plasma concentration (Tmax) of BMS-955176/GSK3532795

End point title	Time of maximum observed plasma concentration (Tmax) of BMS-955176/GSK3532795 ^[46]
-----------------	---

End point description:

Tmax was evaluated from the blood samples collected at pre-dose (morning) and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 and 24 hours after administration of BMS-955176/GSK3532795 60 mg or 120 mg or 180 mg with TDF/ FTC on study Week 2 (Days 12 to 16).

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (morning) and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 and 24 hours on study Week 2 (Days 12 to 16)

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: There are no statistical data to report.

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8 ^[47]	6 ^[48]	10 ^[49]	
Units: Hour				
median (full range (min-max))	4 (1.6 to 8.2)	4.29 (4 to 5.1)	5.5 (1 to 12)	

Notes:

[47] - Evaluable PK Population

[48] - Evaluable PK Population

[49] - Evaluable PK Population

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the concentration-time curve in one dosing interval (AUC [tau]) of BMS-955176/GSK3532795

End point title	Area under the concentration-time curve in one dosing interval (AUC [tau]) of BMS-955176/GSK3532795 ^[50]
-----------------	---

End point description:

AUC (tau) was evaluated from the blood samples collected at pre-dose (morning) and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 and 24 hours after administration of BMS-955176/GSK3532795 mg or 120 mg or 180 mg with TDF/ FTC on study Week 2 (Days 12 to 16).

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (morning) and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 and 24 hours on study Week 2 (Days 12 to 16)

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8 ^[51]	6 ^[52]	10 ^[53]	
Units: Hour*ng/ mL				
geometric mean (geometric coefficient of variation)	34226.751 (± 18.73)	55251.956 (± 32.88)	87128.359 (± 20.79)	

Notes:

[51] - Evaluable PK Population

[52] - Evaluable PK Population

[53] - Evaluable PK Population

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

On-treatment SAEs and non-serious AEs were collected from the start of the study treatment up to 24 weeks. They were planned to be assessed up to 96 weeks, but it was analyzed up to Week 24 as the study was terminated.

Adverse event reporting additional description:

On treatment SAEs and non-serious AEs were reported for the Treated Subjects Population.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	BMS-955176/GSK3532795 60 mg + TDF/FTC
-----------------------	---------------------------------------

Reporting group description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 milligrams (mg) active dose, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing efavirenz (EFV) placebo matching 600 mg from Day 1 to Week 48.

Reporting group title	BMS-955176/GSK3532795 120 mg + TDF/FTC
-----------------------	--

Reporting group description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 120 mg active dose, BMS-955176/GSK3532795 placebo matching 60 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg from Day 1 to Week 48.

Reporting group title	BMS-955176/GSK3532795 180 mg + TDF/FTC
-----------------------	--

Reporting group description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 mg active dose, BMS-955176/GSK3532795 120 mg active dose and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg from Day 1 to Week 48.

Reporting group title	EFV 600 mg + TDF/FTC
-----------------------	----------------------

Reporting group description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 placebo matching 60 mg, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV 600 mg active dose from Day 1 to Week 48.

Serious adverse events	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 50 (2.00%)	2 / 52 (3.85%)	1 / 51 (1.96%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			

Investigations HEPATIC ENZYME INCREASED alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 50 (0.00%) 0 / 0 0 / 0	 0 / 52 (0.00%) 0 / 0 0 / 0	 0 / 51 (0.00%) 0 / 0 0 / 0
Injury, poisoning and procedural complications OVERDOSE alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 50 (0.00%) 0 / 0 0 / 0	 1 / 52 (1.92%) 0 / 1 0 / 0	 0 / 51 (0.00%) 0 / 0 0 / 0
Cardiac disorders VENTRICULAR EXTRASYSTOLES alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 50 (0.00%) 0 / 0 0 / 0	 0 / 52 (0.00%) 0 / 0 0 / 0	 0 / 51 (0.00%) 0 / 0 0 / 0
Gastrointestinal disorders ABDOMINAL PAIN alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 50 (0.00%) 0 / 0 0 / 0	 1 / 52 (1.92%) 1 / 1 0 / 0	 0 / 51 (0.00%) 0 / 0 0 / 0
COLITIS ULCERATIVE alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 50 (2.00%) 0 / 1 0 / 0	 0 / 52 (0.00%) 0 / 0 0 / 0	 0 / 51 (0.00%) 0 / 0 0 / 0
TOOTHACHE alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 50 (0.00%) 0 / 0 0 / 0	 0 / 52 (0.00%) 0 / 0 0 / 0	 0 / 51 (0.00%) 0 / 0 0 / 0

Respiratory, thoracic and mediastinal disorders			
PNEUMOTHORAX SPONTANEOUS			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
INTERVERTEBRAL DISCITIS			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	EFV 600 mg + TDF/FTC		
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 53 (9.43%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Investigations			
HEPATIC ENZYME INCREASED			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
OVERDOSE			
alternative dictionary used: MedDRA 19.0			

subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
VENTRICULAR EXTRASYSTOLES			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
ABDOMINAL PAIN			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
COLITIS ULCERATIVE			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TOOTHACHE			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
PNEUMOTHORAX SPONTANEOUS			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
INTERVERTEBRAL DISCITIS			
alternative dictionary used: MedDRA 19.0			

subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
URINARY TRACT INFECTION			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	BMS-955176/GSK353279 5 60 mg + TDF/FTC	BMS-955176/GSK353279 5 120 mg + TDF/FTC	BMS-955176/GSK353279 5 180 mg + TDF/FTC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	34 / 50 (68.00%)	38 / 52 (73.08%)	41 / 51 (80.39%)
Nervous system disorders			
Dizziness			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	0 / 50 (0.00%)	2 / 52 (3.85%)	2 / 51 (3.92%)
occurrences (all)	0	2	2
Headache			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	0 / 50 (0.00%)	3 / 52 (5.77%)	5 / 51 (9.80%)
occurrences (all)	0	3	6
General disorders and administration site conditions			
Fatigue			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	3 / 50 (6.00%)	1 / 52 (1.92%)	3 / 51 (5.88%)
occurrences (all)	3	1	3
Pyrexia			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	1 / 50 (2.00%)	1 / 52 (1.92%)	3 / 51 (5.88%)
occurrences (all)	1	1	3
Ear and labyrinth disorders			

Vertigo alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	0 / 52 (0.00%) 0	0 / 51 (0.00%) 0
Gastrointestinal disorders Diarrhoea alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all) Nausea alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all) Abdominal pain alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all) Vomiting alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all) Abdominal pain upper alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all) Dyspepsia alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	19 / 50 (38.00%) 25 3 / 50 (6.00%) 3 4 / 50 (8.00%) 5 2 / 50 (4.00%) 2 3 / 50 (6.00%) 4 0 / 50 (0.00%) 0	20 / 52 (38.46%) 28 4 / 52 (7.69%) 4 5 / 52 (9.62%) 7 5 / 52 (9.62%) 6 3 / 52 (5.77%) 5 5 / 52 (9.62%) 5	32 / 51 (62.75%) 52 6 / 51 (11.76%) 7 11 / 51 (21.57%) 15 3 / 51 (5.88%) 4 4 / 51 (7.84%) 5 1 / 51 (1.96%) 1
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2	1 / 52 (1.92%) 1	0 / 51 (0.00%) 0
Skin and subcutaneous tissue disorders			

Rash alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	2 / 52 (3.85%) 2	1 / 51 (1.96%) 1
Rash macular alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	0 / 52 (0.00%) 0	1 / 51 (1.96%) 1
Psychiatric disorders Insomnia alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	1 / 52 (1.92%) 1	8 / 51 (15.69%) 8
Abnormal dreams alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	4 / 52 (7.69%) 5	1 / 51 (1.96%) 1
Anxiety alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 2	1 / 52 (1.92%) 1	1 / 51 (1.96%) 1
Musculoskeletal and connective tissue disorders Back pain alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	1 / 52 (1.92%) 1	4 / 51 (7.84%) 4
Muscle spasms alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	1 / 52 (1.92%) 1	3 / 51 (5.88%) 3
Arthralgia alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 52 (0.00%) 0	0 / 51 (0.00%) 0
Infections and infestations			

Nasopharyngitis alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	4 / 50 (8.00%) 6	3 / 52 (5.77%) 4	5 / 51 (9.80%) 6
Pharyngitis alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	5 / 50 (10.00%) 5	3 / 52 (5.77%) 4	3 / 51 (5.88%) 5
Upper respiratory tract infection alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 6	6 / 52 (11.54%) 7	2 / 51 (3.92%) 2
Influenza alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2	5 / 52 (9.62%) 5	1 / 51 (1.96%) 1
Bronchitis alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2	3 / 52 (5.77%) 3	0 / 51 (0.00%) 0
Sinusitis alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 4	1 / 52 (1.92%) 1	1 / 51 (1.96%) 1
Conjunctivitis alternative dictionary used: MedDRA 19.0 subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 3	0 / 52 (0.00%) 0	0 / 51 (0.00%) 0

Non-serious adverse events	EFV 600 mg + TDF/FTC		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	41 / 53 (77.36%)		
Nervous system disorders Dizziness alternative dictionary used: MedDRA 19.0			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Headache</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>19 / 53 (35.85%)</p> <p>22</p> <p>6 / 53 (11.32%)</p> <p>7</p>		
<p>General disorders and administration site conditions</p> <p>Fatigue</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pyrexia</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 53 (1.89%)</p> <p>1</p> <p>2 / 53 (3.77%)</p> <p>2</p>		
<p>Ear and labyrinth disorders</p> <p>Vertigo</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 53 (5.66%)</p> <p>3</p>		
<p>Gastrointestinal disorders</p> <p>Diarrhoea</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Nausea</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Abdominal pain</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting</p> <p>alternative dictionary used: MedDRA 19.0</p>	<p>6 / 53 (11.32%)</p> <p>7</p> <p>8 / 53 (15.09%)</p> <p>9</p> <p>0 / 53 (0.00%)</p> <p>0</p>		

<p>subjects affected / exposed</p> <p>1 / 53 (1.89%)</p> <p>occurrences (all)</p> <p>1</p> <p>Abdominal pain upper</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>0 / 53 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Dyspepsia</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>0 / 53 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>3 / 53 (5.66%)</p> <p>occurrences (all)</p> <p>3</p>			
<p>Skin and subcutaneous tissue disorders</p> <p>Rash</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>3 / 53 (5.66%)</p> <p>occurrences (all)</p> <p>3</p> <p>Rash macular</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>3 / 53 (5.66%)</p> <p>occurrences (all)</p> <p>3</p>			
<p>Psychiatric disorders</p> <p>Insomnia</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>2 / 53 (3.77%)</p> <p>occurrences (all)</p> <p>2</p> <p>Abnormal dreams</p> <p>alternative dictionary used: MedDRA 19.0</p> <p>subjects affected / exposed</p> <p>5 / 53 (9.43%)</p> <p>occurrences (all)</p> <p>5</p> <p>Anxiety</p> <p>alternative dictionary used: MedDRA 19.0</p>			

subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	3		
Musculoskeletal and connective tissue disorders			
Back pain			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	2 / 53 (3.77%)		
occurrences (all)	2		
Muscle spasms			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences (all)	0		
Arthralgia			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	3		
Infections and infestations			
Nasopharyngitis			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	2 / 53 (3.77%)		
occurrences (all)	2		
Pharyngitis			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	3		
Upper respiratory tract infection			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences (all)	2		
Influenza			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	3		
Bronchitis			
alternative dictionary used: MedDRA 19.0			

subjects affected / exposed	1 / 53 (1.89%)		
occurrences (all)	1		
Sinusitis			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 April 2015	This amendment served to clarify inclusion/exclusion criteria, clarify virologic failure, clarify resistance testing, correct Sparse PK sample collection time, provide additional details on dosage forms, and modify references to discontinuation due to pregnancy to ensure consistency.
22 May 2015	This amendment served to clearly define most contraception methods, incorporate a post-dosing safety follow-up visit, require women of childbearing potential (WOCBP) to follow study instructions, add a time to loss of virologic response (TLOVR) analysis and define virologic rebound, add information on laboratory assessments, update the division of AIDS (DAIDS) toxicity table as appendices, and clarify that AIDS history will be taken at screening.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported